Angiogenesis is a highly controlled event which depends on the proper equilibrium of activators and inhibitors present within the microenvironment. Hepatocyte Growth Factor (HGF) activates migration and proliferation of endothelial cells and is angiogenic, acting through the tyrosine kinase receptor encoded by the Met protooncogene. To get insights into the molecular mechanisms involved in HGF-induced angiogenesis, we searched for cDNAs dierentially expressed in human endothelial cells exposed to HGF, a potent angiogenic factor. We found that HGF-treated endothelial cells upregulated the expression of Transforming Growth Factor (TGF) b 2 . To understand the signi®cance of this ®nding, we cultured endothelial cells with HGF and TGF b 2 simultaneously. We found that TGF b 2 impairs HGFdependent proliferative and migratory responses. TGF b 2 did not prevent the tyrosine phosphorylation of Met, but it inhibited some signalling pathways activated by HGF. We show that endothelial proliferation induced by HGF required the activation of the MAPK cascade, while HGF-induced endothelial migration was dependent on the tyrosine phosphorylation of Src. Indeed, TGF b 2 inhibited HGF eects because it prevented HGF-induced MAP kinase activation and tyrosine phosphorylation of Src. We suggest that the induction of TGF b 2 by HGF in endothelial cells may represent a physiologic mechanism to counterbalance HGF angiogenic activity. Oncogene (2000) 19, 124 ± 133.
Introduction
Angiogenesis, the process by which new blood vessels are formed, is a complex process which is central to normal development and homeostasis (Folkman, 1995a) . During angiogenesis, the coordinated regulation of a wide variety of molecules, including growth factors and inhibitors, extracellular matrix components and proteolytic enzymes, leads to endothelial cell proliferation, matrix degradation, cellular migration and dierentiation (Folkman and D'Amore, 1996) . It is now clear that angiogenesis is a highly controlled event and depends on the proper temporal and spatial equilibrium of activators and inhibitors present within the microenvironment (Hanahan and Folkman, 1996) . Indeed, uncontrolled angiogenesis contributes to a number of pathological processes, including diabetic retinopathy, rheumatoid arthritis, tumour growth and metastasis (Folkman, 1995b) .
A variety of cytokines and growth factors have been shown to induce new blood vessel formation in vivo, and to aect endothelial behaviour in vitro. Among others, Hepatocyte Growth Factor (HGF), a cytokine of mesenchimal origin, is an angiogenic factor (Grant et al., 1993; Bussolino et al., 1992) . HGF stimulates the endothelial cells to elaborate Immunoprecipitates were resolved on SDS ± PAGE, and proteins were visualized by autoradiography Oncogene (2000) 19, 124 ± 133 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc proteases, degrade the extracellular matrix, migrate and proliferate (Bussolino et al., 1992) . The biological responses mediated by the HGF receptor, which is encoded by the proto-oncogene Met, (Naldini et al., 1991) are triggered by the tyrosine phosphorylation of a single multifunctional docking site located in the receptor's carboxyterminal tail (Ponzetto et al., 1994) ; this sequence interacts with several cytoplasmic transducers (Ponzetto et al., 1994; Pelicci et al., 1995; Weidner et al., 1996) either directly or indirectly.
Since HGF aects endothelial cell function, we assumed that the isolation of dierentially expressed genes in HGF-treated endothelial cells would yield insights into the molecular mechanisms contributing to HGF dependent angiogenesis. Here we report that HGF induces TGF b 2 . In turn, TGF b 2 inhibits some of HGF eects in endothelial cells through interferences with post-receptor signalling.
Results

HGF induces TGF b 2
To obtain cDNAs representing mRNAs regulated by HGF in human endothelial cells, we utilized a modi®ed PCR-based dierential screening approach commonly referred to as RNA ®ngerprinting (Consalez et al., 1996; Dragoni et al., 1998) . We obtained several dierentially expressed clones. Sequence analysis and sequence homology search (EMBL/ GenBank) showed one of these clones denominated HGF induced factor-1 to encode for the carboxyterminal region of TGF b 2 (not shown). The dierential expression of TGF b 2 in HGF treated HUVEC was veri®ed by Northern blot. As shown in Figure 1a , TGF b 2 expression was transiently increased with highest expression at 4 h. Immunoprecipitation of radiolabelled HUVEC revealed that HGF induces the synthesis of TGF b 2 (25 kDa) within 12 h and up to 24 h (Figure 1b) . By ELISA, we observed the gradual accumulation of TGF b 2 in the c d Figure 2 TGF b 2 inhibition of HGF-dependent cell proliferation and migration. (a) HUVEC were treated with various concentrations of TGF b 2 alone or in combination with HGF (30 ng/ml). After 4 days, the cells were harvested by digestion with trypsin and viable cells counted using a Burker chamber. Data are expressed as percentage of the control as described in Materials and methods. (b) HUVEC monolayers were used for migration assays as described in Materials and methods. (c) HUVEC were exposed to TGF b 2 (30 ng/ml) 3 h before or 3 h after the addition of HGF (30 ng/ml). Migration assay was performed as described.
(d) HUVEC were cultured in the presence of HGF (10 ng/ml) and a neutralizing antibody against TGF b 2 . After 3 days, migration assay was performed as described conditioned media obtained from HUVEC exposed to HGF (Table 1) . Part of the secreted TGF b 2 was shown to be proteolytically cleaved to yield biologically active TGF b 2 (data not shown).
TGF b 2 prevents HGF-dependent biological eects in endothelial cells
To get insights into the biological signi®cance of the induction of TGF b 2 expression by HGF, we studied whether TGF b 2 interfered with HGF action in endothelial cells. HUVEC were plated in the presence of HGF and increasing concentrations of TGF b 2 and counted after 4 days. In agreement with previous studies (Merwin et al., 1991) , TGF b 2 alone did not aect endothelial cell growth at any concentration tested (Figure 2a ). When the cells were cultured with both HGF and TGF b 2 , TGF b 2 prevented the growth stimulation by HGF in a dose dependent manner (Figure 2a ). We also evaluated the eect of TGF b 2 on HGF induced migration. Indeed, TGF b 2 attenuated HGF-induced HUVEC migration ( Figure 2b ). As shown in Figure 2c , TGF b 2 fully inhibited cell migration when administered to HUVEC before or together with HGF. In contrast, TGF b 2 had no eect when administered 3 h after HGF (Figure 2c ), indicating that TGF b 2 mainly aects early events required by HGF to exert its activity in HUVEC. To prove that HGF-stimulated TGF b 2 inhibits HGF dependent migration, we cultured HUVEC in the presence of HGF (10 ng/ ml) and a neutralizing antibody (10 mg/ml) against TGF b 2 for 3 days before performing a migration assay. As shown in Figure 2d , the neutralizing antibody against TGF b 2 enhances endothelial response to HGF. Because a high degree of heterogeneity has been observed in endothelial cells originated from vessels of dierent caliber (McCarthy et al., 1991) , the eect of TGF b 2 on HGF activity was evaluated in bovine micro-and macro-vascular endothelial cells, BCE and BAE respectively. As shown in Figure 3a ,b, TGF b 2 inhibits the mitogenic and motogenic activities of HGF both in BAE and BCE cells.
We tested whether the inhibitory eects of TGF b 2 on HGF action was speci®c for endothelial cells. Interestingly, we noted that TGF b 2 did not inhibit scatter activity by HGF of MDCK cells (not shown). We also evaluated whether TGF b 2 inhibitory eect was restricted to HGF; preliminary results indicate that TGF b 2 also inhibits FGFinduced endothelial cell growth and migration (not shown).
It has been reported that HGF induces the uPAuPAR proteolytic network (Bussolino et al., 1992) , which plays a crucial role in cell surface associated degradation of the pericellular matrix, thus facilitating cell migration and invasion. However, we were unable to observe any modulation in the expression of the aforementioned system in HUVEC treated with HGF, as detected by Northern blot, Western blot and zymography (not shown).
TGF b 2 interferes with HGF signalling
To explain the aforementioned results, we anticipated that a defect in receptor signalling may exist when endothelial cells are co-treated with TGF b 2 and HGF. Figure 4 shows that the HGF receptor, encoded by the proto-oncogene Met, is functional when TGF b 2 is present; indeed both in the presence and in the absence of TGF b 2 , Met was phosphorylated on tyrosine residues. We next investigated whether TGF b 2 could interfere with HGF-induced intracellular signalling cascade. Met initiates signalling by the formation of a protein complex containing both adaptor and signalling proteins (Ponzetto et al., 1994) .
Activation of Src, a cytosolic tyrosine kinase, has been implicated in HGF-induced cell motility (Rahimi et al., 1998) . Moreover, Src is implicated in endothelial cell migration (Cary et al., 1996) . We observed that HGF did not induce tyrosine phosphorylation of Src in the presence of TGF b 2 (Figure 5a ). Accordingly, PP1, which is a selective pyrazolo pyrimidine-type inhibitor of Src (Kapus et al., 1999) , inhibited HGF-induced cell migration at a concentration as low as 5 mM (Figure  5b ), while it did not signi®cantly alter cell proliferation (Figure 5c ).
HGF-induced growth of epithelial cells requires the stimulation of the MAP-kinase cascade (Ponzetto et al., 1996) . Since erk-2/p42
MAPK is activated by a kinase cascade that induces phosphorylation of threonine and tyrosine residues, we evaluated the levels of tyrosine phosphorylated erk-2/p42 MAPK in HUVEC treated with HGF and TGF b 2 alone or in combination. Within 30 min, HGF alone (30 ng/ml) upregulated the levels of tyrosine phosphorylated erk-2/p42 MAPK , while TGF b 2 inhibited HGF-dependent phosphorylation of erk-2/ p42 MAPK ( Figure 6a ). In agreement with this result, HGF did not stimulate MAP kinase activity when coincubated with TGF b 2 in a MAPK assay which utilized PHAS-1 as a substrate of phosphorylation ( Figure 6b ) (Haystead et al., 1994) . The MEK/MAPK pathway can be selectively blocked by PD098059, a synthetic inhibitor shown to inhibit the activation of MEK in response to a variety of stimuli (Alessi et al., 1995) . Indeed, PD098059 completely blocked MAPK activation in endothelial cells exposed to HGF (data not shown). As shown in Figure 7a , PD098059 (0.1 mM) markedly inhibited HGF-induced cell growth, while it did not aect HGF induced cell migration (Figure 7b ).
Discussion
Endothelial cell migration and proliferation are processes that initiate the formation of capillaries during normal development and during tumour angiogenesis (Folkman, 1995b; Folkman and D'Amore, 1996; Hanahan and Folkman, 1996) . The same processes are believed to control wound healing responses of blood vessels after traumatic injury, graft placement, or organ transplantation (Folkman, 1995a) . Because HGF plays a role in neovascularization (Grant et al., 1993; Bussolino et al., 1992) , we anticipated that the isolation of dierentially expressed genes in HGFtreated endothelial cells may yield insights into the molecular mechanisms involved in angiogenesis and its regulation.
Here we report that HGF upregulates TGF b 2 in endothelial cells. TGF bs are polypeptides that act hormonally to regulate dierentiation and proliferation of a variety of cell types, among which endothelial cells (Merwin et al., 1991) . In particular, several studies have examined the eects of TGF b 1 and b 2 on such endothelial cell response as growth, dierentiation and migration, demonstrating that endothelial cells are much more responsive to TGF b 1 than TGF b 2 (Merwin et al., 1991) . In agreement with these results, we found that TGF b 2 alone at the concentrations used does not aect endothelial migration and proliferation. Our ®nding that TGF Since the biological responses mediated by HGF are triggered by the tyrosine phosphorylation of Met (Ponzetto et al., 1994) , it is noteworthy that TGF b 2 did not interfere with the tyrosine phosphorylation of a b c Figure 5 Role of Src in mediating HGF eects on endothelial cells. (a) HUVEC were treated for 20 min with HGF (30 ng/ml) and TGF b 2 (30 ng/ml) alone or in combination. Cell extracts were immunoprecipitated with a monoclonal antibody against phosphotyrosine. Immunoprecipitates were resolved on 8% SDS ± PAGE and Western blot was performed using an anti-Src antibody. (b) HUVEC were treated with HGF (30 ng/ml) in the presence or in the absence of PP1. After 4 days, the cells were harvested by digestion with trypsin and viable cells counted using a Burker chamber (c) HUVEC monolayers treated with 30 ng/ml of HGF with or without PP1 were used for migration assays as described in Materials and methods Met. Various intracellular signalling pathways are activated by Met and mediate a speci®c cell response. In epithelial cells, it is established that scattering is dependent on phosphatidylinositol-3-OH kinase and Rac activation (Ridley et al., 1995) , while growth requires the stimulation of the Ras-MAPK (Ponzetto et al., 1996) cascade and the STAT pathway is necessary for tubulogenesis (Boccaccio et al., 1998) . To understand how TGF b 2 inhibits HGF, we elucidated which intracellular signalling pathways are able to discriminate between HGF-induced cell migration and proliferation in endothelial cells. In this regard, it is noteworthy that PP1, a selective Src family inhibitor (Kapus et al., 1999) , strongly reduced HUVEC migration in response to HGF, while it did not signi®cantly inhibit cell proliferation. Interestingly, we found that TGF b 2 blocks HGF-dependent tyrosine phosphorylation of Src. Indeed, Src functions in the regulation of endothelial migration through the phosphorylation on tyrosine residues of several cytoskeletal proteins (Romer et al., 1994) , including cortactin, which plays a major role in endothelial locomotion (Huang et al., 1998) . Consistent with our data, Src activity is required for HGF-induced motility in various cell types, among which mammary carcinoma cells (Rahimi et al., 1998) . It is interesting to note that TGF b 1 , which shares the same receptors with TGF b 2 , downregulates Src family tyrosine kinase activity in PC3 cells . In addition, in rat ®broblasts TGF b 1 signi®cantly decreased Src kinase activity and protein abundance, mainly by accelerating Src degradation (Fukuda et al., 1998) . The tyrosine receptor induced Ras-MAPK pathway has been shown to be essential for cell proliferation (Ponzetto et al., 1996) . Indeed, in the presence of the MEK inhibitor PD098059, HGF did not stimulate endothelial proliferation. In addition, while TGF b 2 alone had no eect on the MAPK cascade, it markedly reduced MAPK activity induced by HGF. We conclude that TGF b 2 inhibits HGF-stimulated cell proliferation because it inhibits HGF activation of MAPK activity. The role of MAPK in TGF b signalling is controversial. Indeed, TGF b 2 stimulates acute and chronic activation of the MAPK cascade in rat mesangial cells (Huwiler et al., 1994) , and TGF b activates Ras and ERK2 in epithelial cells (Hartsough and Mulder, 1995) . On the contrary, TGF b inhibits the tyrosine phosphorylation of multiple proteins, among which ERK2, in interleukin 5-treated eosinophils (Pazdrak et al., 1995) . It is noteworthy that a member of the MAPKKK family, namely TAK1, has been isolated and shown to mediate TGF b signal transduction (Yamaguchi et al., 1995) . These con¯icting reports could be due to dierent sensitivity to TGF b by dierent cell types. In this context, it is interesting to note that we observed an inhibitory eect of TGF b 2 on HGF-induced cell migration and proliferation both in micro-and macro-vascular endothelial cells. In contrast, TGF b 2 did not aect HGF-stimulated scattering in epithelial MDCK cells, thus indicating that TGF b 2 action is rather speci®c for endothelial cells. The inhibition of the MAPK cascade by TGF b 2 in endothelial cells seems intriguing, since it is known that MAPK activation is crucial in angiogenesis (Eliceiri et al., 1998) .
TGF b plays an important role in controlling various endothelial functions, among which vascular development. Indeed, while the nascent endothelial tube requires VEGF for survival, the ®nal stages of vessel formation depend upon TGF b. In particular, TGF b leads to vessel stabilization, because it inhibits endothelial cell proliferation and migration and induces pericyte/smooth muscle cell dierentiation (Hirschi et al., 1999) . Vascular development and angiogenesis share various characteristics and both result from a precise spacial and temporal balance between stimulators and inhibitors. Several angiogenic molecules have been isolated, among which HGF, which has been shown to play a role in neovascularization of tumours of dierent histotypes as well as in acute myeloid leukaemia (Grant et al., 1993; Bussolino et al., 1992) . In the context of angiogenesis induced by HGF, our data suggest that HGF, released by tumour cells, activates its own receptor on endothelial cells and stimulates endothelial migration and proliferation, two crucial steps in the formation of new vessels. HGF also induces the synthesis of TGF b 2 , which inhibits HGF actions through interference with HGF intracellular signalling. On these bases, we propose that HGF-induced TGF b 2 acts as an endogenous, physiologic inhibitor a b Figure 6 TGF b 2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b 2 . Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 antibody and Western blot was performed using a polyclonal antibody against erk-2/p42 MAPK . (b) MAPK activity in HUVEC treated with HGF and TGF b 2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described of HGF, capable of counteracting HGF dependent angiogenesis.
Materials and methods
RNA ®ngerprinting
One mg of total mRNA from endothelial cells treated with recombinant HGF (Sigma) was reverse transcribed using an oligo(dT) primer. The cDNAs were then ampli®ed by PCR in the presence of [ 32 P]dCTP using the following primers: 3'-TCT GG AAC CGG-5' and 3'-GGG TCG CGA ACA-5'. PCR products were separated on a denaturing polyacrylamide gel and autoradiographed. Several dierentially expressed genes were identi®ed. The bands corresponding to dierentially expressed genes were excised from the polyacrylamide gel, electroeluted, re-ampli®ed by PCR, cloned in Bluescript and sequenced as described (Consalez et al., 1996; Dragoni et al., 1998) . Double-stranded sequence analysis was performed using the T7 Sequencing kit (Pharmacia) following the manufacturer's instruction. The DNA sequences were analysed by the Analyze and Interpret programs of the Mac Molly Suite (Berlin, Germany). Sequence analysis and sequence homology search (EMBL/GenBank) showed one of these clones denominated HGF induced factor-1 to encode for the 3' region of TGF b 2 .
Puri®cation of RNA and Northern blot
Cells were treated with HGF (10 ng/ml) for dierent times, rinsed with phosphate buered saline and lyzed in 4 M guanidinium isothiocyanate. RNA was puri®ed as described (Maniatis et al., 1982) . RNA was electrophoresed on a 1% a b Figure 7 Role of MAPK in mediating HGF eects on endothelial cells. (a) HUVEC were treated with HGF (30 ng/ml) in the presence or in the absence of PD098059 (0.1 mM). After 4 days, the cells were harvested by digestion with trypsin and viable cells counted using a Burker chamber. (b) HUVEC monolayers treated with 30 ng/ml of HGF with or without PD098059 (0.1 mM) were used for migration assays as described above agarose gel containing 2.2 M formaldehyde, capillary blotted onto nylon membranes and UV crosslinked. TGF b 2 and GAPDH were labelled with a random primer labelling kit (Ambion). Filters were hybridized in 0.5 M sodium phosphate (pH 7.2) containing 7% SDS, 1 mM EDTA and 20% formamide at 658C for 20 h and extensively washed at high stringency. RNA was visualized by autoradiography.
Cell culture, proliferation and migration assays HUVEC-C were from ATCC and cultured in M199 containing 10% FCS, ECGS (150 mg/ml) and heparin (5 U/ ml) (growing medium) on gelatin coated dishes (Dragoni et al., 1998) . Bovine aortic endothelial cells (BAE) and bovine adrenal medulla capillary endothelial cells (BCE) (both provided by P Mignatti, New York, USA) were grown in dMEM supplemented with 10% FCS on gelatin-coated dishes.
Proliferation assays were performed by seeding HUVEC at low density (7500/cm 2 ) in growth medium. After 48 h of starvation in M199 containing 1% FCS, HGF and TGF b 2 were added either alone or in combination. BAE and BCE were seeded (5000/cm 2 ) in growth medium, starved in dMEM with 0.5% FCS for 48 h and incubated with HGF, TGF b 2 or HFG and TGF b 2 simultaneously. In a dierent set of experiments HUVEC were incubated in the presence of HGF (30 ng/ml) and either PP1 (5 mM) or PD098059 (0.1 mM). After 96 h, cells were trypsinized and counted using a Burker chamber. Data are expressed as percentages of the stimulation of cell proliferation exerted by the growing medium when compared to starved cells. The results are always representative of three independent experiments, and the variation was less than 12%.
Migration of HUVEC, BAE and BCE treated as reported above was determined using an in vitro model of wound repair as previously described (Gar®nkel et al., 1996) . Brie¯y, con¯uent endothelial cells were wounded and the number of cells migrating from the wound origin were counted with a light microscope at 1006 magni®cation using a grid. The values represent the mean+s.d. of ®ve ®elds with each condition tested in duplicate and three separate experiments performed.
Immunological methods
To immunoprecipitate TGF b 2 , HUVEC were incubated with 150 mCi/ml [ 35 S]Methionine in Methionine-free medium for 6 h. Cells were then washed, lysed in ice cold RIPA buer and centrifuged. Lysates were immunoprecipitated with 10 mg/ml anti-TGF b 2 (Santa Cruz). The immunocomplexes were bound to protein G-Sepharose, extensively washed, eluted in Laemmli buer at 958C for 5 min, resolved on 12% SDS ± PAGE and autoradiographed. The ELISA assay to measure the amounts of TGF b 2 secreted by HUVEC treated with HGF was from R&D System and performed according to the manufacturer's instructions. To neutralize TGF b 2 , the neutralizing antibody against TGF b 2 from R&D System was added to culture medium.
To detect Met, HUVEC were lysed in RIPA buer and incubated with a mixture of the monoclonal anti-Met antibody DN-30 and DO-24 (Maier et al., 1996) . After 6 h, protein G-Sepharose was added. Bound proteins were eluted by boiling in SDS sample buer, separated by electrophoresis in a 8% polyacrylamide gel under non reducing conditions, and transferred onto a nitrocellulose membrane. The blot was incubated with anti-phosphotyrosine antibodies and with secondary anti-rabbit antibodies conjugated with alkaline phosphatase (Promega). The blot was then stripped and incubated with a polyclonal anti-Met antibody (Santa Cruz) (Maier et al., 1996) .
To detect Src, cell lysates (200 mg) were immunoprecipitated with the monoclonal anti-phosphotyrosine antibody PY20 as described above, resolved by SDS ± PAGE, transferred to nitrocellulose sheets at 150 mA for 16 h, and probed with anti-Src antibodies (10 mg/ml) (Santa Cruz). Secondary antibodies were labelled with horse-radish peroxidase (Pierce, Rockford, IL, USA). The SuperSignal chemiluminescence kit (Pierce) was used to detect immunoreactive proteins. Since activated erk-2/p42
MAPK is phosphorylated also on tyrosine residues, we detected activated erk-2/ p42
MAPK by immunoprecipitating cell lysates with PY20. Western blot was performed using a rabbit polyclonal antierk-2/p42 MAPK antibody (Wu et al., 1998) .
MAP kinase assay
MAP kinase activity was measured using the MAP kinase assay kit from Stratagene according to the manufacturer's instructions. Brie¯y, the phosphorylation of PHAS-1 was evaluated in 40 ml reaction mixture containing 25 mM HEPES, 10 mM magnesium acetate, 50 mM ATP, 2 mCi of g-[
32
]ATP and 50 mg of cell extracts obtained from HUVEC treated for 15 min with HGF and TGF b 2 alone or in combination or untreated. Each reaction was incubated for 10 min at 308C, then mixed with 20 ml of 46 sample buer, analysed by SDS ± PAGE and autoradiographed.
